Table 2.
Meta-analysis of CCR5 polymorphism and the risk of atherosclerotic disease with a dominant model (Δ32/Δ32 or wt/Δ32)
| Category | N | Subjects, n cases/controls | Heterogeneity | OR (95% CI) | Z test | |
|---|---|---|---|---|---|---|
|
| ||||||
| Ph | I2 (%) | |||||
| Overall | 13 | 5321/4283 | < 0.00001 | 77 | 0.93 (0.69- 1.24) | Z = 0.52; PZ = 0.60 |
| Adjustment by ethnicity | ||||||
| Caucasian | 10 | 4748/3582 | < 0.0001 | 74 | 0.77 (0.58-1.02) | Z = 1.82; PZ = 0.07 |
| Asian | 3 | 573/701 | 0.63 | 0 | 2.29 (1.44-3.64)§ | Z = 3.51; PZ = 0.0004 |
| Adjustment by subtypes of AS | ||||||
| CAD | 5 | 3638/1671 | 0.42 | 0 | 1.06 (0.89-1.26)§ | Z = 0.66; PZ = 0.51 |
| MI | 6 | 1093/1527 | < 0.0001 | 87 | 0.77 (0.37-1.61) | Z = 0.70; PZ = 0.48 |
| IS | 2 | 590/1085 | 0.57 | 0 | 0.91 (0.71-1.17)§ | Z = 0.71; PZ = 0.48 |
| Mean age level | ||||||
| > 50 | 8 | 4467/3014 | 0.0003 | 75 | 0.94 (0.70-1.25) | Z = 0.44; PZ = 0.66 |
| < 50 | 5 | 996/1163 | 0.004 | 74 | 1.05 (0.50-2.20) | Z = 0.14; PZ = 0.89 |
| Status of HWE | ||||||
| yes | 11 | 4994/3838 | 0.16 | 0 | 1.05 (0.92-1.19)§ | Z = 0.73; PZ = 0.46 |
| no | 2 | 423/418 | 0.32 | 0 | 0.37 (0.25-0.53)§ | Z = 5.42; PZ < 0.00001 |
| Source of controls | ||||||
| PB | 5 | 943/1203 | < 0.00001 | 87 | 1.34 (0.57-3.18) | Z = 0.67; PZ = 0.50 |
| HB | 7 | 4341/2917 | 0.75 | 0 | 0.99 (0.86-1.13)§ | Z = 0.19; PZ = 0.85 |
Abbreviations: AS, atherosclerosis; CAD, coronary artery disease; MI, myocardial infarction; IS, ischemic stroke; HWE, hardy-weinberg equilibrium; PB, population-based; HB, hospital-based; N, number of invealed studies; Ph, P values for heterogeneity of Q test;
§
Fixed-effects model;
PZ < 0.05, indicate significant association.